

Rita Murri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2140187/publications.pdf>

Version: 2024-02-01

112
papers

4,547
citations

101535

36
h-index

110368

64
g-index

113
all docs

113
docs citations

113
times ranked

4750
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning and Antibiotic Management. <i>Antibiotics</i> , 2022, 11, 304.	3.7	2
2	Cefiderocol for Severe Carbapenem-Resistant <i>A. baumannii</i> Pneumonia: Towards the Comprehension of Its Place in Therapy. <i>Antibiotics</i> , 2022, 11, 3.	3.7	20
3	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. <i>Journal of Chemotherapy</i> , 2021, 33, 435-439.	1.5	2
4	Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy. <i>Viruses</i> , 2021, 13, 371.	3.3	132
5	The Role of Early Procalcitonin Determination in the Emergency Department in Adults Hospitalized with Fever. <i>Medicina (Lithuania)</i> , 2021, 57, 179.	2.0	6
6	Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis. <i>Medicina (Lithuania)</i> , 2021, 57, 656.	2.0	4
7	Prognostic Role of Serum Procalcitonin Measurement in Adult Patients Admitted to the Emergency Department with Fever. <i>Antibiotics</i> , 2021, 10, 788.	3.7	6
8	Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review. <i>Viruses</i> , 2021, 13, 2110.	3.3	65
9	Procalcitonin, white blood cell count and C-reactive protein as predictors of <i>S. aureus</i> infection and mortality in infective endocarditis. <i>International Journal of Cardiology</i> , 2020, 301, 190-194.	1.7	22
10	Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department. <i>Internal and Emergency Medicine</i> , 2020, 15, 119-125.	2.0	11
11	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
12	Comparative performance evaluation of Wako β -glucan test and Fungitell assay for the diagnosis of invasive fungal diseases. <i>PLoS ONE</i> , 2020, 15, e0236095.	2.5	20
13	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 164.	4.1	20
14	Social media as a tool for scientific updating at the time of COVID pandemic: Results from a national survey in Italy. <i>PLoS ONE</i> , 2020, 15, e0238414.	2.5	16
15	Early procalcitonin determination in the emergency department and clinical outcome of community-acquired pneumonia in old and oldest old patients. <i>European Journal of Internal Medicine</i> , 2020, 79, 51-57.	2.2	6
16	A proposal for a comprehensive approach to infections across the surgical pathway. <i>World Journal of Emergency Surgery</i> , 2020, 15, 13.	5.0	15
17	Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 637-644.	1.8	15
18	Management of mycotic aorto-iliac aneurysms: a 30-year monocentric experience. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 3274-3281.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 19-24.	2.7	11
20	Risk factors for recurrence in patients with <i>Clostridium difficile</i> infection due to 027 and non-027 ribotypes. <i>Clinical Microbiology and Infection</i> , 2019, 25, 474-480.	6.0	15
21	Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 338-345.	2.5	8
22	Direct use of eazyplex [®] SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream infections.	2.7	11
23	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	3.9	81
24	Use of procalcitonin as a tool for antibiotic stewardship. <i>Future Microbiology</i> , 2019, 14, 77-79.	2.0	0
25	The role of procalcitonin outside of the Intensive Care Unit (ICU): a multidisciplinary approach. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 2978-2985.	0.7	1
26	IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. <i>Clinical Infectious Diseases</i> , 2018, 66, 1815-1816.	5.8	5
27	Systematic clinical management of patients with candidemia improves survival. <i>Journal of Infection</i> , 2018, 77, 145-150.	3.3	13
28	A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 167-173.	2.9	11
29	Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing <i>Klebsiella pneumoniae</i> infections: retrospective single-center case series. <i>Infection</i> , 2017, 45, 209-213.	4.7	21
30	Antibiotic stewardship from toolkit to local implementation: the "gutta cavat lapidem"™ strategy. <i>Future Microbiology</i> , 2017, 12, 935-938.	2.0	3
31	Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. <i>AIDS Research and Therapy</i> , 2016, 13, 18.	1.7	6
32	Liver Resection for Primary Intrahepatic Stones: Focus on Postoperative Infectious Complications. <i>World Journal of Surgery</i> , 2016, 40, 433-439.	1.6	7
33	Nursing home residence is associated with spread of <i>Clostridium difficile</i> ribotype 027 in central Italy. <i>Journal of Hospital Infection</i> , 2016, 94, 201-203.	2.9	4
34	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. <i>International Journal for Quality in Health Care</i> , 2016, 28, 502-507.	1.8	19
35	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
36	Initial antifungal strategy does not correlate with mortality in patients with candidemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 187-193.	2.9	22

#	ARTICLE	IF	CITATIONS
37	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016, 48, 48-55.	2.8	5
38	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
39	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. <i>Future Microbiology</i> , 2015, 10, 15-20.	2.0	8
40	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23
41	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) <i>Tj ETQq1 1 0.784314 rgt /Overlock 10 T</i>	3.0	45
42	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. <i>Antiviral Therapy</i> , 2013, 18, 153-160.	1.0	52
43	The Challenge of Identifying Resistant-Organism Pneumonia in the Emergency Department: Still Navigating on the Erie Canal?. <i>Clinical Infectious Diseases</i> , 2012, 54, 199-201.	5.8	2
44	Management of Recurrent Cutaneous Abscesses During Therapy With Infliximab. <i>Clinical Therapeutics</i> , 2011, 33, 1993-1996.	2.5	6
45	Physicians' knowledge of health-related quality of life and perception of its importance in daily clinical practice. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 43.	2.4	24
46	Incidence of Malignancies in HIV-Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 1316-1321.	5.8	56
47	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 411-412.	2.1	11
48	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. <i>Aids</i> , 2010, 24, 2408-2412.	2.2	27
49	Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals. <i>AIDS Patient Care and STDs</i> , 2009, 23, 35-39.	2.5	8
50	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. <i>Infection</i> , 2009, 37, 168-178.	4.7	5
51	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2008, 22, 291-299.	2.5	33
52	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. <i>AIDS Patient Care and STDs</i> , 2008, 22, 577-585.	2.5	41
53	Sexual dysfunction in HIV infection. <i>Lancet, The</i> , 2007, 369, 905-906.	13.7	19
54	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2007, 86, 225-226.	1.8	23

#	ARTICLE	IF	CITATIONS
55	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-65.	1.0	15
56	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-1066.	1.0	54
57	Is "Once-Daily" Regimen a Key Strategy for Improving Adherence to Antiretroviral Regimens?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 259-260.	2.1	7
58	Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 23-30.	2.1	44
59	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. <i>Quality of Life Research</i> , 2006, 15, 377-390.	3.1	27
60	Quality of Life and Body Image in the Assessment of Psychological Impact of Lipodystrophy: Validation of the Italian Version of Assessment of Body Change and Distress Questionnaire. <i>Quality of Life Research</i> , 2006, 15, 173-178.	3.1	46
61	Access to gynecological services and Papanicolau tests in HIV-infected Italian women: A questionnaire survey. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006, 18, 376-378.	1.2	5
62	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 407-416.	2.1	46
63	Partnership of HIV-Infected Women and Health Status. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 502-503.	2.1	0
64	Highly active antiretroviral therapy. <i>BMJ: British Medical Journal</i> , 2005, 330, 681-682.	2.3	3
65	Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. <i>International Journal of STD and AIDS</i> , 2004, 15, 254-259.	1.1	84
66	Patient-reported and physician-estimated adherence to HAART. <i>Journal of General Internal Medicine</i> , 2004, 19, 1104-1110.	2.6	60
67	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. <i>Psychosomatics</i> , 2004, 45, 394-402.	2.5	231
68	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. <i>Antiviral Therapy</i> , 2004, 9, 291-296.	1.0	32
69	Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. <i>Journal of Infectious Diseases</i> , 2003, 187, 1934-1943.	4.0	96
70	Determinants of health-related quality of life in HIV-infected patients. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2003, 15, 581-590.	1.2	104
71	Neurocognitive Performance and Quality of Life in Patients with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 643-652.	1.1	107
72	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 184-190.	2.1	64

#	ARTICLE	IF	CITATIONS
73	Nonnucleoside Reverse Transcriptase Inhibitor-Containing Regimens Are Associated With Increased Satisfaction With Sexual Life. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 532-534.	2.1	5
74	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. <i>HIV Clinical Trials</i> , 2003, 4, 99-106.	2.0	38
75	Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S136-S139.	2.1	238
76	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S123-S127.	2.1	390
77	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S158-S162.	2.1	55
78	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002, 16, 369-379.	2.2	189
79	Declining Tuberculosis and Drug Resistance Rate Among HIV-Positive Patients at an Italian Teaching Hospital in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 546-547.	2.1	3
80	Adherence to Protease Inhibitors. <i>Annals of Internal Medicine</i> , 2001, 134, 625.	3.9	2
81	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 49-55.	2.1	2
82	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 49-55.	2.1	4
83	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. <i>Journal of NeuroVirology</i> , 2001, 7, 323-328.	2.1	68
84	Potent anti-retroviral therapy with or without zidovudine for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001, 7, 364-368.	2.1	64
85	Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition. <i>HIV Clinical Trials</i> , 2001, 2, 323-329.	2.0	31
86	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 445-449.	2.1	405
87	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. <i>Aids</i> , 2001, 15, 1579-1581.	2.2	67
88	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	65
89	Circulating Levels and <i>in vivo</i> Production of β ² -Chemokines, Interferon β ³ , and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 835-843.	1.1	12
90	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	120

#	ARTICLE	IF	CITATIONS
91	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. <i>Aids</i> , 2000, 14, F117-F121.	2.2	72
92	The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Journal of Infectious Diseases</i> , 2000, 182, 1077-1083.	4.0	113
93	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. <i>Aids</i> , 2000, 14, 1655-1656.	2.2	11
94	Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. <i>Aids</i> , 2000, 14, 1660-1662.	2.2	42
95	Clinical and Virological Monitoring During Treatment with Intrathecal Cytarabine in Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 1999, 28, 624-628.	5.8	55
96	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. <i>Lancet</i> , The, 1999, 353, 1974.	13.7	16
97	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 461.	2.1	23
98	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 461.	2.1	24
99	Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 365-371.	0.3	46
100	Disease-Related Factors Associated With Health-Related Quality of Life in People With Nonadvanced HIV Disease Assessed Using an Italian Version of the MOS-HIV Health Survey. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 350-356.	0.3	45
101	Low-dose dapsone, co-trimoxazole, and survival in <i>Pneumocystis carinii</i> primary prophylaxis. <i>Aids</i> , 1996, 10, 1046-1047.	2.2	1
102	Cognitive Impairment in Asymptomatic Stages of HIV Infection. <i>European Neurology</i> , 1996, 36, 125-133.	1.4	35
103	PCR detection of <i>Toxoplasma gondii</i> DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. <i>Journal of Medical Microbiology</i> , 1996, 45, 472-476.	1.8	72
104	Imbalance between <i>Pneumocystis carinii</i> cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. <i>Journal of Medical Microbiology</i> , 1996, 45, 146-148.	1.8	16
105	Karnofsky Performance Status and Assessment of Global Health Status. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 294.	0.3	18
106	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia and toxoplasmic encephalitis. <i>Aids</i> , 1995, 9, 1343-1350.	2.2	62
107	Fluconazole for Primary Prophylaxis of AIDS-associated Cryptococcosis: A Case-control Study. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 235-237.	1.5	14
108	Presumptive Clinical Criteria Versus Endoscopy in the Diagnosis of <i>Candida</i> Esophagitis at Various HIV-1 Disease Stages. <i>Endoscopy</i> , 1995, 27, 371-376.	1.8	14

#	ARTICLE	IF	CITATIONS
109	Prognostic factors of early fatal outcome and long-term survival in patients with <i>Pneumocystis carinii</i> pneumonia and acquired immunodeficiency syndrome. <i>European Journal of Epidemiology</i> , 1993, 9, 183-189.	5.7	16
110	Primary central nervous system lymphoma and brain biopsy in AIDS. <i>Lancet, The</i> , 1993, 341, 1411-1412.	13.7	15
111	Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet, The</i> , 1992, 340, 788.	13.7	18
112	Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 635-636.	2.5	10